Janssen Pharmaceuticals (Janssen) recently announced its plans to seek U.S. Food and Drug Administration (FDA) approval for its Ketamine-based depression treatment this year. The announcement follows the company having recently revealing promising Phase III clinical study results for the nasal spray treatment.
Study data on consumers with treatment-resistant depression displayed that a combination of the treatment and a newly initiated oral antidepressant resulted in a statistically significant reduction in depressive symptoms compared to a placebo. In another party of the study, the same treatment approach for participants age 65 and up with treatment-resistant depression resulted in meaningful effects that were nearly statistically significant. Major depressive disorder currently affects almost 300 million people globally.
Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium. Janssen conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anesthesia and analgesia, gastrointestinal disorders, cancer, and others.
This was reported by PharmaLive on May 7, 2018.
Contact Information: Janssen Pharmaceuticals, 1000 U.S. Route 202 South, Raritan, New Jersey 08869; (908) 722-5393; Website: www.janssen.com